Coronary Artery Bypass Grafts or Percutaneous Coronary Intervention for High Risk Patients

NCT ID: NCT05534698

Last Updated: 2022-09-15

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 1550 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-10-31
• Study Completion Date: 2033-02-28

Brief Summary

Most patients with Left Ventricular Systolic Dysfunction (LVSD) or heart failure (HF) have coronary artery disease (CAD) while some patients also have renal disease. Life-saving revascularization is underperformed in patients with LVSD or HF due to CAD, and especially if there is concomitant renal disease. We hypothesize that PCI will be non-inferior to CABG for all-cause mortality and recurrent myocardial infarction (MI), stroke or hospitalization for HF. To compare revascularization by PCI versus by CABG, we will perform a multicentre, open-label, parallel, randomized, controlled trial in patients with severe CAD who belong to defined categories of moderate-to-high risk characteristics, where guidelines acknowledge that both PCI and CABG are relevant treatment options.

Detailed Description

The STICH trial demonstrated a reduction in overall mortality after 10 years, but the 5-year analyses did not show significant benefits of CABG versus medical therapy. The extension of the STICH study, the STICHES study established the superiority of CABG over medical therapy for all-cause mortality (58.9% versus 66.1%; HR 0.84, 95%CI: 0.73-0.97; p = 0.02) over 9.8 years. Thus, these studies suggest that to offset the early operative risks of CABG, 10-year survival is needed. As many patients with HF and/or LVSD are elderly, both clinicians and patients are often unwilling to accept increased short-term risk even if they might eventually achieve long-term benefit, and thus not favour CABG. The available evidence suggest that PCI is feasible for patients with ischemic LVSD, and that PCI may yield long-term mortality rates like CABG with lower short-term morbidity The planned trial is a multicentre, open-label, parallel, randomized, controlled trial comparing revascularization by CABG versus by PCI in patients with severe CAD and at high risk, where guidelines accept both CABG and PCI as suitableand mortality. High risk is defined as patients with LVEF <45%, (irrespectively of clinical HF and severe renal disease), left anterior descending (LAD) disease in one- or two vessel disease, three-vessel disease with a SYNTAX score of up to 22 and left main disease with a SYNTAX score of up to 32.

The trial is powered for non-inferiorty.

Conditions

IHD; LV Dysfunction

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

PCI

Revascularization by PCI

Group Type: ACTIVE_COMPARATOR

PCI

Intervention Type: PROCEDURE

Revascularization by PCI

CABG

Revascularization based on CABG.

Group Type: ACTIVE_COMPARATOR

CABG

Intervention Type: PROCEDURE

Revascularization by CABG

Interventions

PCI

Revascularization by PCI

Intervention Type: PROCEDURE

CABG

Revascularization by CABG

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Age ≥ 18 years

• LVEF<45% with or without HF medication
• Heart team believes that a meaningful revascularization can be achieve both by PCI and by CABG
• Patients with severe CAD, where guidelines suggest equipoise between PCI and CABG

Exclusion Criteria

• Decompensated HF requiring inotropic/adrenergic support, invasive or non-invasive ventilation or intra-aortic balloon pump/ ventricular assist device therapy less than 48 hours prior to randomization

• Recent (< 1 month) ST-elevation myocardial infarction
• Recent (< 1 month) type 2 myocardial infarction ▪ Valvular heart disease or any other cardiac conditions (for example, left ventricular aneurysm) indicating the need for surgical repair/replacement
• Prohibitive bleeding risk or clinical scenario mandating avoidance of long-term dual antiplatelet therapy
• Pregnancy

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Danish Study Group

NETWORK

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Lars V Køber, MD

Role: STUDY_CHAIR

Rigshospitalet, Denmark

Locations

Rigshospitalet, University of Copenhagen

Copenhagen, , Denmark

Countries

Denmark

Central Contacts

Lars V Køber, MD

Role: CONTACT

lk@heart.dk

31120540

Facility Contacts

Lars Køber, MD, D.Sci

Role: primary

LK@HEART.DK

35 45 33 76

Other Identifiers

H-21000675

Identifier Type: -

Identifier Source: org_study_id